YD Bio Limited
Key statistics
from XBRL data in SEC filingsAI briefing
from the latest 10-K, 10-Q and 8-K eventsYD Bio Ltd is a Cayman Islands-incorporated medical laboratory services company based in Taipei, Taiwan, and listed on Nasdaq.
What they do
YD Bio Limited is a Cayman Islands exempted company operating in the Services-Medical Laboratories industry. Its principal offices are located in Nangang District, Taipei City, Taiwan. The company became a public reporting entity through a Business Combination involving Breeze Holdings Acquisition Corp. and YD Biopharma Limited. It has 70,789,261 ordinary shares and 15,142,911 warrants outstanding as of December 31, 2025.
Revenue drivers
- Medical laboratory services — The company operates in the Services-Medical Laboratories industry, which is its sole identified line of business.
- Revenue growth — Annual revenue increased from $350,131 in 2023 to $510,360 in 2024 and $596,817 in 2025.
- Business Combination — The company became public through a merger with Breeze Holdings Acquisition Corp. and YD Biopharma Limited, owning 100% of YD Biopharma.
Recent performance
Revenue rose to $596,817 in 2025 from $510,360 in 2024 and $350,131 in 2023. Net income swung from $13,560 in 2023 to a net loss of $1.4 million in 2024 and $8.3 million in 2025. Diluted EPS was $0.00 in 2023, negative $0.02 in 2024, and negative $0.12 in 2025. Operating cash flow deteriorated from negative $55,657 in 2023 to negative $1.2 million in 2024 and negative $6.6 million in 2025. At December 31, 2025, total assets were $13.8 million, total liabilities were $16.6 million, and shareholder equity was negative $2.9 million, with $6.0 million in cash.
Strategy
The filing excerpts provided do not contain specific statements about the company's strategic direction, investments, or priorities. The company operates as a medical laboratory services provider based in Taiwan. It became a public company through a Business Combination in order to access public markets. No other strategy details are available in the provided source material.
Risks
- Accumulating losses — The company reported net losses of $1.4 million in 2024 and $8.3 million in 2025, with negative operating cash flow of $6.6 million in 2025.
- Negative shareholder equity — At December 31, 2025, total liabilities of $16.6 million exceeded total assets of $13.8 million, resulting in negative shareholder equity of $2.9 million.
- Small revenue base — Annual revenue was only $596,817 in 2025, leaving limited scale to absorb operating costs.
- Foreign private issuer status — As a Cayman Islands company listed on Nasdaq, the company is subject to different disclosure and governance requirements than U.S. domestic issuers.
Outlook
The provided filing excerpts do not include a management outlook section or forward-looking guidance. The company's recent financial performance shows widening losses and negative operating cash flow. No statements about future plans, product development, or financial targets are available in the source material.